ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Biologic agents"

  • Abstract Number: 1369 • 2019 ACR/ARP Annual Meeting

    Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy

    Ji-Won Kim1, Jin-Sun Kong 2, Youngjae Park 3 and Wan-Uk Kim 3, 1Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, 2Catholic University of Korea, College of Medicine, Seoul, Republic of Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    Background/Purpose: Previously, we demonstrated the direct pro-inflammatory role of the vascular endothelial growth factor (VEGF) and the placenta growth factor (PlGF), and angiogenic factors in…
  • Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting

    Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry

    Xue Han1, Joshua Bryson 1, David C Crosby 1, Michael Evans 2 and Gabriela Schmajuk 3, 1Bristol-Myers Squibb, Princeton, 2University of California San Francisco, San Francisco, 3UCSF, SFVAMC Division of Rheumatology, San Francisco, CA

    Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…
  • Abstract Number: 1437 • 2019 ACR/ARP Annual Meeting

    Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease

    Sho Sasaki1, Akira Ishii 2, Mai Sugiyama 2, Yuto Izumi 2, Yoko Nakagome 2, Kazuki Hirano 3, Takayoshi Kurabayashi 1, Noriko Sasaki 2, Chiho Yamada 2 and Shinji Sato 4, 1Tokai Universitiy School of Medicine, Isehara, Japan, 2Tokai University School of Medicine, Isehara, Japan, 3Tokai University School of Medicine, Isehara, 4Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan

    Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…
  • Abstract Number: 1496 • 2019 ACR/ARP Annual Meeting

    Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study

    Josef Smolen1, Panagiotis Athanassiou 2, Paul Bergmans 3, Irina Bondareva 4, Kurt De Vlam 5, Elisa Gremese 6, Beatriz Joven-Ibáñez 7, Tatiana Korotaeva 8, Wim Noël 9, Michael Nurmohamed 10, Petros Sfikakis 11, Stefan Siebert 12, Pavel Smirnov 13, Elke Theander 14 and Laure Gossec 15, 1Medical University of Vienna, Vienna, Austria, 2General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, 3Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, 4GUZ Kemerovo Regional Clinical Hospital, Kemerovo, Russia, 5University Hospitals Leuven, Leuven, Belgium, 6Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, 7Hospital Universitario 12 de Octubre, Madrid, Spain, 8Nasonova Research Institute of Rheumatology, Moscow, Russia, 9Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, 10Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, 11Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 12Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 13Biostatistics and Medical Affairs, Janssen, Moscow, Russia, 14Biostatistics and Medical Affairs, Janssen, Solna, Sweden, 15Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France

    Background/Purpose: Among the treatment options for PsA, IL-12/23 inhibition with ustekinumab (UST) was the first new biologic mode of action after TNF inhibitors (TNFi). Few…
  • Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting

    Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?

    Santiago Rodrigues-Manica1, Alexandre Sepriano 2, Fernando Pimentel-Santos 1, Nélia Gouveia 3, Anabela Barcelos 4, Jaime Branco 1, Miguel Bernardes 5, Raquel Miriam-Ferreira 5, Elsa Vieira-Sousa 6, Sofia Barreira 6, Filipe Vinagre 7, Raquel Roque 7, Helena Santos 8, Nathalie Madeira 8, João Rovisco 9, Alexandra Daniel 9 and Sofia Ramiro 10, 1CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, 2Leiden University Medical Center, Leiden, Netherlands, 3CEDOC, NOVA-Medical School, Lisbon, Portugal, Lisboa, Portugal, 4Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, 5Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, 6Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, 7Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, 8Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 9Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Coimbra, Portugal, 10Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands

    Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…
  • Abstract Number: 573 • 2018 ACR/ARHP Annual Meeting

    Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis

    Pascal Hilliquin1, Thomas Barnetche2, Guy Baudens3, Ralph Niarra4, Isabelle Idier5 and Alain Saraux6, 1Rheumatology, Hôpital Sud Francilien, Corbeil-Essonne, France, 2Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, 3Rheumatology, CHR Valenciennes, Valenciennes, France, 4Biostatistics, Keyrus of behalf of Roche SAS, Boulogne-Billancourt, France, 5Medical department, Chugai Pharma France, Paris La Defense, France, 6Rheumatology, CHU Brest, Brest, France

    Background/Purpose: In France, tocilizumab (TCZ) subcutaneous (sc) 1st prescription and yearly renewal are restricted to hospital. Monitoring may be done by both office-based or hospital…
  • Abstract Number: 1615 • 2018 ACR/ARHP Annual Meeting

    Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

    Moa Lee1, Rishi J. Desai2, Yinzhu Jin3, Gregory Brill1, Alexis Ogdie4 and Seoyoung C. Kim1, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cardiovascular disease is a major comorbidity in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Increasing evidence suggests a potential reduction in the risk…
  • Abstract Number: 2624 • 2018 ACR/ARHP Annual Meeting

    Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis

    Dongze Wu1, Tingting Xu2, Isaac T. Cheng1, Steven H.M. Lam1, Jiang Yue1, Priscilla Wong1, Edmund Li1, Tena K. Li1 and Lai-Shan Tam3, 1Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, 2China Center for Health Development Studies, Peking University, Beijing, China; Department of Health Policy and Administration, Peking University School of Public Health, Beijing, China, Beijing, China, 3Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong

    Background/Purpose: For patients with psoriatic arthritis (PsA) failing the first TNF-inhibitor, switching to biologic DMARDs [bDMARDs] with different mechanism of actions (swapping strategy) may be…
  • Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting

    Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis

    Ted R. Mikuls1, Amrita Bath2, Bryant R. England3, Michael J. Duryee4, Carlos D. Hunter4, Joel Kremer5, Dimitrios A. Pappas6,7, William H. Robinson8, Jeffrey R. Curtis9 and Geoffrey M. Thiele10, 1Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 2Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 4Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5Albany Medical Center, Albany, NY, 6Columbia University, New York, NY, 7Corrona, LLC, Waltham, MA, 8Stanford University, Palo Alto, CA, 9University of Alabama at Birmingham, Birmingham, AL, 10University of Nebraska Medical Center, Omaha, NE

    Background/Purpose:  Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents.  As previous studies have…
  • Abstract Number: 1655 • 2018 ACR/ARHP Annual Meeting

    Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate

    Leonieke van Mens1, Jet de Jong2, Inka Fluri1, Marleen van de Sande3, Michael Nurmohamed4, M.R. Kok5, Arno van Kuijk6 and Dominique Baeten2, 1Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 3Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 4Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, 5Rheumatology, Maasstad Ziekenhuis, Rotterdam, Netherlands, 6Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands

    Background/Purpose: In inflammatory arthritis such as RA, early initiation of highly effective targeted treatments is a successful strategy to aim for sustained remission.1 Here we…
  • Abstract Number: 2676 • 2018 ACR/ARHP Annual Meeting

    SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment

    Ioannis Parodis1,2, Sharzad Emamikia1,2, Alvaro Gomez1 and Katerina Chatzidionysiou2,3, 1Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 2Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: In systemic lupus erythematosus (SLE), organ damage is associated with unfavourable disease courses and premature mortality. We aimed at investigating the impact of organ…
  • Abstract Number: 590 • 2018 ACR/ARHP Annual Meeting

    Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years

    Patricia Bogas1, Chamaida Plasencia2, Victoria Navarro-Compán3, Diego Benavent2, Gabriela Gonzalez2, María Gema Bonilla Hernán2, Irene Monjo1 and Juan Molina1, 1Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, 2Rheumatology, La Paz University Hospital, Madrid, Spain, 3Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain

    Background/Purpose: In the last two decades the treatment in patients with rheumatoid arthritis (RA) has undergone major advances, especially due to the appearance of new…
  • Abstract Number: 1704 • 2018 ACR/ARHP Annual Meeting

    Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies

    Ioannis Parodis1,2, Sharzad Emamikia1,2, Iva Gunnarsson1,2, Ronald F. van Vollenhoven2,3 and Katerina Chatzidionysiou1,4, 1Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 2Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 3Amsterdam Rheumatology and Immunology Center ARC, Department of Clinical Immunology & Rheumatology, University of Amsterdam, Amsterdam, The Netherlands, Amsterdam, Netherlands, 4Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Drug development in systemic lupus erythematosus (SLE) has been challenging. One of the reasons can be traced in the choice of outcome measures. In…
  • Abstract Number: 2823 • 2018 ACR/ARHP Annual Meeting

    Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor

    Daniela Santos Faria1, Mónica Eusébio2, Joana Leite Silva3, Joana Ramos Rodrigues1, Joana Sousa Neves1, Ana Catarina Duarte4, Carina Lopes5, Ana Valido6, Joana Dinis6, João Freitas7, Mariana Santiago7, Raquel Ferreira8, Sara Ganhão9, Luís Cunha Miranda10, Daniela Peixoto1, Filipa Teixeira1, Sérgio Alcino1, Carmo Afonso1, José Tavares Costa3 and Maria José Santos11, 1Rheumatology, ULSAM, Ponte de Lima, Portugal, 2Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, 3Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, 4Rheumatology, Hospital Garcia de Orta, Almada, Portugal, 5Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, 6Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 7Rheumatology, Centro Hospitalar e Universitário de Coimbra, CHUC-EPE, Coimbra, Portugal, 8Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, 9Rheumatology, Centro Hospitalar de São João, Porto, Portugal, 10Instituto Português de Reumatologia, Lisbon, Portugal, 11Reuma.pt, Almada, Portugal, Almada, Portugal

    Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are highly effective treatments for active Rheumatoid Arthritis (RA). However, up to 40% of patients either fail to respond…
  • Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting

    Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study

    Naohiro Sugitani1,2, Eiichi Tanaka1, Eisuke Inoue1,3, Eri Sugano1, Kumiko Saka1, Moeko Ochiai1, Rei Yamaguchi1, Yoko Shimizu1, Naoki Sugimoto1, Katsunori Ikari1, Ayako Nakajima1,2, Atsuo Taniguchi1 and Hisashi Yamanaka4, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, 3Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, 4Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies